Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.
Castella M, Boronat A, Martín-Ibáñez R, Rodríguez V, Suñé G, Caballero M, Marzal B, Pérez-Amill L, Martín-Antonio B, Castaño J, Bueno C, Balagué O, González-Navarro EA, Serra-Pages C, Engel P, Vilella R, Benitez-Ribas D, Ortiz-Maldonado V, Cid J, Tabera J, Canals JM, Lozano M, Baumann T, Vilarrodona A, Trias E, Campo E, Menendez P, Urbano-Ispizua Á, Yagüe J, Pérez-Galán P, Rives S, Delgado J, Juan M. Castella M, et al. Among authors: baumann t. Mol Ther Methods Clin Dev. 2018 Dec 6;12:134-144. doi: 10.1016/j.omtm.2018.11.010. eCollection 2019 Mar 15. Mol Ther Methods Clin Dev. 2018. PMID: 30623002 Free PMC article.
Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia.
Ferrer G, Hodgson K, Pereira A, Juan M, Elena M, Colomer D, Roué G, Aymerich M, Baumann T, Montserrat E, Moreno C. Ferrer G, et al. Among authors: baumann t. Leuk Lymphoma. 2011 Nov;52(11):2064-8. doi: 10.3109/10428194.2011.591008. Epub 2011 Jun 27. Leuk Lymphoma. 2011. PMID: 21707303
Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations.
López C, Delgado J, Costa D, Conde L, Ghita G, Villamor N, Navarro A, Cazorla M, Gómez C, Arias A, Muñoz C, Baumann T, Rozman M, Aymerich M, Colomer D, Cobo F, Campo E, López-Guillermo A, Montserrat E, Carrió A. López C, et al. Among authors: baumann t. Genes Chromosomes Cancer. 2012 Sep;51(9):881-9. doi: 10.1002/gcc.21972. Epub 2012 May 23. Genes Chromosomes Cancer. 2012. PMID: 22619094
Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance.
López C, Delgado J, Costa D, Villamor N, Navarro A, Cazorla M, Gómez C, Arias A, Muñoz C, Cabezas S, Baumann T, Rozman M, Aymerich M, Colomer D, Pereira A, Cobo F, López-Guillermo A, Campo E, Carrió A. López C, et al. Among authors: baumann t. Genes Chromosomes Cancer. 2013 Oct;52(10):920-7. doi: 10.1002/gcc.22087. Epub 2013 Jul 26. Genes Chromosomes Cancer. 2013. PMID: 23893575
New treatment options for chronic lymphocytic leukemia.
Delgado J, Baumann T, Santacruz R, Montserrat E. Delgado J, et al. Among authors: baumann t. Expert Opin Pharmacother. 2014 Apr;15(6):823-32. doi: 10.1517/14656566.2014.891017. Epub 2014 Feb 22. Expert Opin Pharmacother. 2014. PMID: 24559127 Review.
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S. Delgado J, et al. Among authors: baumann t. Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997154 Free PMC article. No abstract available.
High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
Dlouhy I, Filella X, Rovira J, Magnano L, Rivas-Delgado A, Baumann T, Martínez-Trillos A, Balagué O, Martínez A, González-Farre B, Karube K, Gine E, Delgado J, Campo E, López-Guillermo A. Dlouhy I, et al. Among authors: baumann t. Leuk Res. 2017 Aug;59:20-25. doi: 10.1016/j.leukres.2017.05.014. Epub 2017 May 17. Leuk Res. 2017. PMID: 28544905
625 results